Tissue | Expression Dynamics | Abbreviation |
Breast | | IDC: Invasive ductal carcinoma |
DCIS: Ductal carcinoma in situ |
Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:004593618 | Prostate | BPH | negative regulation of phosphate metabolic process | 124/3107 | 441/18723 | 5.95e-10 | 2.90e-08 | 124 |
GO:005122217 | Prostate | BPH | positive regulation of protein transport | 93/3107 | 303/18723 | 6.94e-10 | 3.25e-08 | 93 |
GO:001056318 | Prostate | BPH | negative regulation of phosphorus metabolic process | 124/3107 | 442/18723 | 6.94e-10 | 3.25e-08 | 124 |
GO:004232617 | Prostate | BPH | negative regulation of phosphorylation | 110/3107 | 385/18723 | 2.08e-09 | 8.35e-08 | 110 |
GO:000193317 | Prostate | BPH | negative regulation of protein phosphorylation | 97/3107 | 342/18723 | 2.74e-08 | 8.11e-07 | 97 |
GO:004586118 | Prostate | BPH | negative regulation of proteolysis | 98/3107 | 351/18723 | 5.43e-08 | 1.49e-06 | 98 |
GO:005134818 | Prostate | BPH | negative regulation of transferase activity | 78/3107 | 268/18723 | 1.94e-07 | 4.29e-06 | 78 |
GO:000646916 | Prostate | BPH | negative regulation of protein kinase activity | 62/3107 | 212/18723 | 2.81e-06 | 4.45e-05 | 62 |
GO:003367315 | Prostate | BPH | negative regulation of kinase activity | 67/3107 | 237/18723 | 4.15e-06 | 6.25e-05 | 67 |
GO:19040292 | Prostate | BPH | regulation of cyclin-dependent protein kinase activity | 34/3107 | 98/18723 | 1.00e-05 | 1.39e-04 | 34 |
GO:000974318 | Prostate | BPH | response to carbohydrate | 67/3107 | 253/18723 | 4.20e-05 | 4.48e-04 | 67 |
GO:003428418 | Prostate | BPH | response to monosaccharide | 61/3107 | 225/18723 | 4.34e-05 | 4.60e-04 | 61 |
GO:004340915 | Prostate | BPH | negative regulation of MAPK cascade | 51/3107 | 180/18723 | 5.20e-05 | 5.35e-04 | 51 |
GO:000974617 | Prostate | BPH | response to hexose | 58/3107 | 219/18723 | 1.33e-04 | 1.19e-03 | 58 |
GO:00457863 | Prostate | BPH | negative regulation of cell cycle | 91/3107 | 385/18723 | 2.10e-04 | 1.71e-03 | 91 |
GO:000974915 | Prostate | BPH | response to glucose | 55/3107 | 212/18723 | 3.42e-04 | 2.55e-03 | 55 |
GO:1904030 | Prostate | BPH | negative regulation of cyclin-dependent protein kinase activity | 14/3107 | 33/18723 | 4.08e-04 | 2.97e-03 | 14 |
GO:000167810 | Prostate | BPH | cellular glucose homeostasis | 44/3107 | 172/18723 | 1.71e-03 | 9.87e-03 | 44 |
GO:007133310 | Prostate | BPH | cellular response to glucose stimulus | 39/3107 | 151/18723 | 2.52e-03 | 1.35e-02 | 39 |
GO:00716928 | Prostate | BPH | protein localization to extracellular region | 82/3107 | 368/18723 | 2.59e-03 | 1.39e-02 | 82 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
CAMK2N1 | SNV | Missense_Mutation | novel | c.203N>C | p.Lys68Thr | p.K68T | Q7Z7J9 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.563) | TCGA-AJ-A5DW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CAMK2N1 | SNV | Missense_Mutation | novel | c.196N>A | p.Val66Met | p.V66M | Q7Z7J9 | protein_coding | deleterious_low_confidence(0) | possibly_damaging(0.706) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
CAMK2N1 | SNV | Missense_Mutation | novel | c.185G>T | p.Arg62Met | p.R62M | Q7Z7J9 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.993) | TCGA-FI-A2D5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatinum | PD |
CAMK2N1 | SNV | Missense_Mutation | | c.113N>G | p.Ala38Gly | p.A38G | Q7Z7J9 | protein_coding | tolerated_low_confidence(1) | benign(0) | TCGA-CC-A7IH-01 | Liver | liver hepatocellular carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
CAMK2N1 | SNV | Missense_Mutation | | c.219N>T | p.Lys73Asn | p.K73N | Q7Z7J9 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.991) | TCGA-50-5930-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Chemotherapy | taxotere | PD |
CAMK2N1 | SNV | Missense_Mutation | novel | c.195N>A | p.Asp65Glu | p.D65E | Q7Z7J9 | protein_coding | tolerated_low_confidence(0.57) | benign(0.005) | TCGA-78-7155-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
CAMK2N1 | SNV | Missense_Mutation | | c.95N>A | p.Thr32Asn | p.T32N | Q7Z7J9 | protein_coding | deleterious_low_confidence(0.01) | benign(0) | TCGA-97-7937-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
CAMK2N1 | SNV | Missense_Mutation | novel | c.220N>T | p.Ala74Ser | p.A74S | Q7Z7J9 | protein_coding | tolerated_low_confidence(1) | benign(0.003) | TCGA-39-5040-01 | Lung | lung squamous cell carcinoma | Male | <65 | III/IV | Chemotherapy | cisplatin | PD |